Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 8/20 | 0.38 |
| ▸ | MC1R | Q01726 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | GRB2 | P62993 | 5/20 | 0.34 |
| ▸ | TACR2 | P21452 | 3/20 | 0.34 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27433060 | 1.00 | MC4R (0.38) | MC4RMC1RTACR1GRB2TACR2 | |
| SCHEMBL27430917 | 0.92 | MC4R (0.41) | MC4RMC1RTACR1GRB2KISS1R | |
| SCHEMBL27429085 | 0.92 | MC4R (0.39) | MC4RMC1RTACR1GRB2KISS1R | |
| SCHEMBL27429167 | 0.92 | TACR1 (0.36) | MC4RTACR1GRB2KISS1R | |
| SCHEMBL27428931 | 0.91 | TACR1 (0.38) | MC4RTACR1GRB2KISS1R | |
| SCHEMBL27429103 | 0.91 | TACR1 (0.36) | MC4RTACR1GRB2KISS1R | |
| SCHEMBL27389137 | 0.91 | TACR1 (0.36) | MC4RTACR1GRB2KISS1R | |
| SCHEMBL27428897 | 0.89 | TACR1 (0.38) | MC4RTACR1GRB2KISS1R | |
| SCHEMBL27430885 | 0.89 | MC4R (0.36) | MC4RTACR1KISS1R | |
| SCHEMBL27428789 | 0.89 | TACR1 (0.36) | MC4RTACR1GRB2KISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | VIP, QPCT, PTMS | MC4R 430/4885MC1R 529/4885TACR1 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.